bemnifosbuvir + digoxin + ruzasvir

This entry refers to the co-administration of the investigational fixed-dose combination (FDC) of bemnifosbuvir and ruzasvir with digoxin, primarily studied in the context of a Phase 1 drug-drug interaction (DDI) trial (NCT06921941). Bemnifosbuvir (AT-527) is an oral guanosine nucleotide prodrug that acts as an inhibitor of the Hepatitis C Virus (HCV) NS5B RNA-dependent RNA polymerase. Ruzasvir (AT-179) is an oral small molecule inhibitor of the HCV NS5A protein. Digoxin is a cardiac glycoside that serves as a sensitive probe substrate for the P-glycoprotein (P-gp) transporter. The study evaluates the potential for the bemnifosbuvir/ruzasvir combination to inhibit P-gp, which can lead to increased plasma exposure of P-gp substrates like digoxin. This antiviral regimen is being developed by Atea Pharmaceuticals for the treatment of chronic HCV infection.

Brand names

Lanoxin (for digoxin)Digitek (for digoxin)Cardoxin (for digoxin)Lanoxicaps (for digoxin)No widely known brand names for the fixed combination of bemnifosbuvir + ruzasvir as of now

Other names

digoxin + BEM + RZRbemnifosbuvir/ruzasvir + digoxin